KEZAR LIFE Aktie

 

 Announced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis Submitted Type C meeting request to the FDA to meet during the fourth quarter of 2025 to discuss the development plan for zetomipzomib in autoimmune hepatitis PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting® 2025 Cash, cash equivalents and marketable securities totaled $101 million as of June 30, 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis,” said Chris Kirk, PhD, CEO and co-founder of Kezar. “We are committed to workin...

Chiang, Pichi Luo - Vorstand - Tag der Transaktion: 2025-07-02...

Schiller, Mark C. - Vorstand - Tag der Transaktion: 2025-07-02...

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Reported positive topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) Cash, cash equivalents and marketable securities totaled $114.4 million as of March 31, 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH,” said Chris Kirk, CEO and co-founder of Kezar. “There has been almost no change over the last three decades in the treatment of this serious chronic disease, and patients and physicians are in need of new and effective therapies. We are encouraged by the promising safety and efficacy data in this difficult-to-treat patien...

Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared to 1 of 8 placebo patients. Median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks (including the ongoing open-label extension), and no disease flares were reported in any zetomipzomib-treated patient achieving CR during study. Favorable safety profile was observed during the 6-month, blinded tre...

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN CARLTON PRECIOUS O.N. IVH CA14306B1076 LODESTAR METALS CORP. PR9 CA54020J1012 PEGASUS MERCANTILE INC. U04 CA70557Y1051 RUBELLITE ENERGY CORP. 6L00 CA7811131050 KEZAR LIFE SC.NEW DL-,001 2KZ0 US49372L2097 MAGNERA CORP. WI DL-,01 W2B US55939A1079 MIND TECHNOL. NEW DL-,01 MI70 US6025663096 MONOPAR THERAP. NEW 1IY0 US61023L2079 NRX PHARM.INC. NEW O.N. B1Q US6294442099 PALVELLA THERAPEUTICS NEW PI6 US6979471090 AB/FROM ONWARDS 17.01.2025 09:41 CET...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL KEZAR LIFE SC.NEW DL-,001 2KZ0 US49372L2097 BAW/UFN...

Instrument ID [21443085] (2KZ0 - US49372L2097) suspended...

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen NO0012547308 Standard Supply AS 29.10.2024 NO0013384651 Standard Supply AS 30.10.2024 Tausch 100:1 US49372L1008 Kezar Life Sciences Inc. 29.10.2024 US49372L2097 Kezar Life Sciences Inc. 30.10.2024 Tausch 10:1 SE0008348262 Expres2ion Biotech Holding AB 29.10.2024 SE0023261292 Expres2ion Biotech Holding AB 30.10.2024 Tausch 40:1...